Synthera®+ Platform

Louvain-la-Neuve, Belgium, December 19, 2025 - IBA (Ion Beam Applications S.A), the world leader in particle accelerator technology with a preeminent position in nuclear medicine, acquires ORA, a global trailblazer in radiochemistry based in Belgium.
 

This acquisition emphasizes IBA’s long-term commitment to the fast-developing and promising field of nuclear medicine. It reinforces IBA’s position at the forefront of innovation in precision oncology enabling for better diagnostic and more personalized patient therapy.
 

The combination of IBA cyclotron leadership with ORA’s cutting-edge technology provides one of the most competitive integrated solutions for hospitals and global radiopharmacy networks looking for high productivity and access to labelling of advanced radioisotopes.
 

This acquisition complements IBA’s existing nuclear medicine strategic initiatives including the co-founding of PanTera for the production of Ac-225, and the shaping of the Accelerate.EU program, as well as the ongoing collaboration with Framatome to explore opportunities in the production of At-211. It is an additional step for IBA on its journey to bring innovation in care to patients and to accelerate the translation of innovative nuclear medicine solutions from bench to bedside.
 

The transaction, for a total consideration of € 15-20 million on a cash-free, debt-free basis, is immediately accretive to IBA Technologies’ revenue and EBITDA and is expected to generate revenue synergies. Financed through IBA’s own funds and existing credit facilities, the acquisition will not have material impact on IBA’s 2025 financial guidance or mid-term outlook.
 

“Joining forces with IBA opens exciting opportunities to scale our NEPTIS^® technology and accelerate innovation in radiochemistry.” said Vincent Tadino, Founder and Chief Executive Officer of ORA. “Together, we will continue to push the boundaries of PET and therapeutic radiochemistry, ensuring our customers have access to the most advanced and reliable solutions for radiopharmaceutical production.”
 

“ORA’s acquisition accelerates our mission to deliver integrated solutions from isotope production to patient-ready therapies, making advanced cancer treatments and diagnostics more accessible worldwide” stated Charles Kumps, President of IBA RadioPharma Solutions, “I am particularly excited that Vincent will continue to lead as Chief Technology Officer of ORA, bringing his vision and deep expertise to our joint efforts.”

To address their needs, the UZ Gent hospital selected IBA and its Synthera^®+ Platform. The hospital was looking for a solution combining reliability, regulatory compliance, and flexibility for evolving scientific requirements.

The hospital adopted a complete Synthera^® configuration, including three synthesis modules, an IFP™ automated cassette loader, an HPLC and an extension module. This set up is used daily for the production of fluorodeoxyglucose (FDG) and other fluorine-18 labelled radiopharmaceuticals.

The Synthera^®+ Platform supports radiopharmacy activities across the entire value chain, from tracer research and development to routine clinical production.

In 2016, our dream started to become a reality: facilitate radiosynthesis by producing ready-to-use consumables with a plug-and-play approach.
 

In 2019, we started the production of disposable tubing kits and other consumables, in its ISO7 cleanroom at Biocant, Portugal.
 

After 9 years, we are proud of what we achieved!
From a start-up to an integrated IBA company, we specialize in the development, production, and sale of disposable cassettes for radioisotopes production and cyclotron liquid target solutions used in radiometals' production.